Is AMRN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

6,830 people get AMRN articles and Market Currents by email alert.

Get email alerts on AMRN »

HEADLINES:

Amarin & Celsion: Post-Earnings Roundup
Quoth the Raven • Wed, May 15 • 35 Comments
Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground
Brian L. Wilson • Mon, May 13 • 32 Comments
Weekly Stock Watch - Week Of May 13, 2013
VFC's Stock House • Sat, May 11 • 2 Comments
5 Stocks To Watch For Gains Next Week
Brian Nichols • Sat, May 11 • 24 Comments
Risky Amarin Sets Its Cash Pile On Fire
Quoth the Raven • Thu, May 9 • 91 Comments
Amarin Corporation CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9 • 1 Comment
Photo Release -- Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations

GlobeNewswire (May 9, 2013)
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
Can Amarin Make Me A Believer This Thursday?
Quoth the Raven • Mon, May 6 • 80 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013

GlobeNewswire (May 3, 2013)
Amarin: The Bull Argument (Or How I Learned To Stop Worrying And Love Vascepa)
Bond Wells • Tue, Apr 30 • 78 Comments
Hedge Funds Are Selling 6 Small Caps Undervalued To Lowest Target Price
Kapitall • Tue, Apr 30 • 2 Comments
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier

GlobeNewswire (Apr 30, 2013)
Amarin's Performance Issues: Here To Stay?
Dallas Salazar • Mon, Apr 29 • 51 Comments
5 Stocks To Watch For Gains Next Week
Brian Nichols • Sun, Apr 28 • 18 Comments
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia

GlobeNewswire (Apr 23, 2013)
Why I'm Adding To My Amarin Short Position
Quoth the Raven • Mon, Apr 22 • 104 Comments
My 5 Summer Stock Market Flings For 2013
Quoth the Raven • Fri, Apr 19 • 63 Comments
By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa
Heather Ingrassia • Thu, Apr 18 • 27 Comments

To learn more about Seeking Alpha Pro, click here.

Amarin & Celsion: Post-Earnings Roundup
Quoth the Raven • Wed, May 15 • 35 Comments
Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground
Brian L. Wilson • Mon, May 13 • 32 Comments
Risky Amarin Sets Its Cash Pile On Fire
Quoth the Raven • Thu, May 9 • 91 Comments
Can Amarin Make Me A Believer This Thursday?
Quoth the Raven • Mon, May 6 • 80 Comments
Amarin: The Bull Argument (Or How I Learned To Stop Worrying And Love Vascepa)
Bond Wells • Tue, Apr 30 • 78 Comments
Amarin's Performance Issues: Here To Stay?
Dallas Salazar • Mon, Apr 29 • 51 Comments
Why I'm Adding To My Amarin Short Position
Quoth the Raven • Mon, Apr 22 • 104 Comments
By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa
Heather Ingrassia • Thu, Apr 18 • 27 Comments
No NCE Decison For Amarin's Vascepa: The Launch Trudges Along
Brian L. Wilson • Tue, Apr 16 • 15 Comments
Amarin's 'All-In' On Vascepa Makes It A Massive Risk
Quoth the Raven • Tue, Mar 26 • 39 Comments
Why Amarin Is Struggling So Much
Brian L. Wilson • Tue, Mar 26 • 34 Comments
Amarin: Is The Trend Still Your Friend?
Brian L. Wilson • Fri, Mar 8 • 7 Comments
Amarin: Liking This Speculative Stock's Risk-Reward Ratio
DoctoRx • Wed, Mar 6 • 23 Comments
Amarin's Descent To $5
Medhanie • Wed, Mar 6 • 72 Comments
A Top Biotech Stock To Own In 2013
Steve Rosenman • Wed, Mar 6 • 70 Comments
Amarin Q4 Call Leaves A Fishy Taste In My Mouth
Quoth the Raven • Fri, Mar 1 • 95 Comments
Amarin: The More You Know The Fishier It Gets
Matt Gravitt • Wed, Feb 27 • 82 Comments
2 Misguided Points For (And Against) Amarin
Brian L. Wilson • Tue, Feb 26 • 14 Comments
Amarin: A Physician's Perspective On Vascepa
DoctoRx • Mon, Feb 25 • 38 Comments
Amarin's Vascepa: 5 Myths Debunked
Heisenberg Principle • Mon, Feb 25 • 85 Comments

Weekly Stock Watch - Week Of May 13, 2013
VFC's Stock House • Sat, May 11 • 2 Comments
5 Stocks To Watch For Gains Next Week
Brian Nichols • Sat, May 11 • 24 Comments
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Hedge Funds Are Selling 6 Small Caps Undervalued To Lowest Target Price
Kapitall • Tue, Apr 30 • 2 Comments
5 Stocks To Watch For Gains Next Week
Brian Nichols • Sun, Apr 28 • 18 Comments
My 5 Summer Stock Market Flings For 2013
Quoth the Raven • Fri, Apr 19 • 63 Comments
Krill Oil's Omega-3s And CaPre: Brought To You By Acasti
Entry Point • Wed, Apr 3 • 19 Comments
Cramer's Mad Money - Top 10 S&P 500 Stocks For The First Quarter (4/1/13)
SA Editor Miriam Metzinger • Tue, Apr 2 • 5 Comments
5 Stocks To Watch For Gains This Week
Brian Nichols • Sat, Mar 30 • 11 Comments
Stock Watch Wednesday, 27 March 2013
VFC's Stock House • Wed, Mar 27 • 26 Comments
Dynavax: A Compelling Buy
Alexander Maxwell • Mon, Mar 25 • 12 Comments
Cramer's Lightning Round - Cisco Is Terrific (3/21/13)
SA Editor Miriam Metzinger • Fri, Mar 22 • 14 Comments
Stock Watch Thursday, 21 March 2013
VFC's Stock House • Thu, Mar 21 • 2 Comments
5 Investing Tricks Of The Trade For Your Arsenal
Quoth the Raven • Mon, Mar 18 • 56 Comments
3 Biotech Stocks That Are Set-Up Nicely For Growth
A John Hodge • Sun, Mar 17 • 7 Comments
Weekly Stock Watch, Week Of 11 March 2013
VFC's Stock House • Mon, Mar 11 • 13 Comments
Trius Therapeutics: New MRSA Treatment Could Bring Billions In Revenues
Scott Matusow • Tue, Mar 5 • 8 Comments
Weekly Stock Watch, Week Of March 4
VFC's Stock House • Mon, Mar 4
VIX - Options Volatility And Market Sonar: Wednesday Recap
Erick McKitterick • Wed, Feb 27 • 6 Comments

Amarin Corporation CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9 • 1 Comment
Amarin Corporation's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28 • 1 Comment
Amarin Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012 • 3 Comments
Amarin's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 8, 2012 • 4 Comments
Amarin Corporation plc Q2 2008 Earnings Call Transcript
Thu, Sep 25, 2008 • 1 Comment

Photo Release -- Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations

GlobeNewswire (May 9, 2013)
Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013

GlobeNewswire (May 3, 2013)
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier

GlobeNewswire (Apr 30, 2013)
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia

GlobeNewswire (Apr 23, 2013)
Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier

GlobeNewswire (Apr 18, 2013)
Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)

GlobeNewswire (Apr 8, 2013)
Lightning Round: Cisco, Amarin & More

at CNBC.com (Mar 21, 2013)
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication

GlobeNewswire (Mar 7, 2013)
Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations

GlobeNewswire (Feb 28, 2013)
Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia

GlobeNewswire (Feb 26, 2013)
Amarin to Report Fourth Quarter and Year-End 2012 Results and Host Conference Call on February 28, 2013

GlobeNewswire (Feb 22, 2013)
Amarin to Present at the CITI 2013 Global Healthcare Conference

GlobeNewswire (Feb 21, 2013)
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication

GlobeNewswire (Feb 12, 2013)
Amarin to Present at the Leerink Swann Global Healthcare Conference 2013

GlobeNewswire (Feb 7, 2013)
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication

GlobeNewswire (Feb 7, 2013)
Amarin Announces Notification of Additional U.S. Patent Allowance for U.S. Application 13/272,520 Based on ANCHOR Clinical Trial Results

GlobeNewswire (Feb 1, 2013)
Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication

GlobeNewswire (Jan 31, 2013)
Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)

GlobeNewswire (Jan 24, 2013)
Amarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results

GlobeNewswire (Jan 23, 2013)
Amarin Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs

GlobeNewswire (Jan 22, 2013)

AMRN vs. ETF Alternatives

Company Description

Amarin Corporation plc is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. Amarin has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate, AMR101,... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: Ireland

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 3:43 PM Shares of Amarin (AMRN -1.1%) rebound somewhat from an earlier dip on news that its Vascepa wasn't in the FDA's Orange Book for April. 5 Comments [Healthcare, On the Move]
Thursday, May 9, 5:43 PM Amarin (AMRN): Q1 EPS of -$0.41 misses by $0.02. (PR) 2 Comments [Earnings, Breaking News, Healthcare]
Tuesday, April 23, 9:15 AM Amarin (AMRN) says the FDA has accepted its supplemental new drug application for Vascepa and set a December 20 target date to complete its regulatory review. The company's seeking approval of the the cholesterol-reducing fish-oil pill as an adjunct to diet for the treatment of high triglycerides with mixed dyslipidemia. Shares +6.2% in pre-market trading. 8 Comments [Healthcare, On the Move]
Tuesday, April 23, 9:10 AM Premarket gainers: MEMS +50%. SCON +46%. NFLX +24%. VECO +14%. COH +12%. ILMN +10%. ARMH +9%. CZR +8%. STM +6%. AMRN +6%.
Losers: IRWD -10%. RSH -7%. IOC -6%. Comment! [On the Move]
Thursday, April 18, 8:53 AM Amarin (AMRN) rises 2.49% premarket after saying the FDA has approved its Supplemental New Drug Application to add Chemport as a supplier of ingredients for Vascepa, AMRN's first approved product. The move comes as AMRN attempts to expand its supply chain and protect Vascepa's commercial potential by "taking advantage of manufacturing barriers to entry." Comment! [Healthcare, On the Move]
Friday, April 12, 12:03 PM Amarin (AMRN -2%) trades lower on reports that Vascepa's exclusivity status isn't in FDA Orange Book update for March. Earlier this week the drug was listed in a report by EvaluatePharma called "The industry's brightest hopes: where are they now?" as the fourth most disappointing drug, having seen lofty expectations of a potential $2B annual market dwindle down to just $505M. 5 Comments [Healthcare, On the Move]
Monday, April 8, 7:25 AM Amarin (AMRN) gains 1.5% premarket after announcing significants reductions in apolipoprotein C-III levels in Phase 3 testing of Vascepa. Apo C-III is thought in inhibit the clearance of triglycerides from the blood. (PR) 1 Comment [Healthcare]
Tuesday, April 2, 11:14 AM MKM Partners' Jon LeCroy is reiterating his Buy rating and $12 price target on Amarin (AMRN +1.8%) following last week's solid Vascepa weekly prescription data. LeCroy notes that if the current growth continues, assuming a wholesale cost of $184 per prescription and a prescription under-reporting rate of 22%, that would imply Q1 Vascepa sales of approximately $2.2M and Q2 of around $11M. So, while the consensus estimates still appear to be slightly high, LeCroy thinks that with stocking, they still could be attainable. 1 Comment [Healthcare, On the Move]
Monday, April 1, 12:47 PM Amarin (AMRN +1%) gets a boost from some positive commentary out of Leerink Swann today, saying that Vascepa's prescription data appears to be tracking well. The firm notes that the largest TRx advance since the drug's launch was recorded last week, and the number of new prescriptions and refills are growing. Looking forward, Leerink thinks the AMRN's ramped-up marketing efforts and moves to obtain Tier 2 reimbursement should further accelerate TRx growth. 1 Comment [Healthcare, On the Move]
Wednesday, March 20, 12:57 PM Amarin (AMRN -0.6%) lags the general market after being being given a less than enthusiastic initiation by analysts at Chardan Capital Markets with a Hold rating and a price target of $8.50 a share. The firm says that the chance for a strategic deal over the near-term is low, and Vascepa faces risks of a tepid debut. 17 Comments [Healthcare]
Thursday, February 28, 5:35 PM Amarin (AMRN): Q4 EPS of -$0.28 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 26, 12:00 PM Amarin (AMRN +1%) gains after saying it's submitted a Supplemental New Drug Application with the FDA seeking approval for the marketing and sale of Vascepa capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides with mixed dyslipidemia. The drug is already approved to treat hypertriglyceridemia, and if cleared for the new indication, it will be the only approved prescription omega 3 therapy for cardiovascular health management in this patient population. Comment! [Healthcare]
Tuesday, February 12, 12:55 PM Amarin (AMRN +1.2%) says the USPTO has granted a Notice of Allowance for patent protection of its Vascepa, a prescription grade omega-3 fatty acid that can help reduce triglyceride levels in adults. The issued patent would have a term that expires no earlier than in 2030. Comment! [Healthcare, On the Move]
Friday, January 18, 2:46 PM Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. 4 Comments [Healthcare, On the Move]
Wednesday, January 2, 3:56 PM Amarin Corporation (AMRN +0.5%) says it's submitted a Supplemental New Drug Application to the FDA seeking approval for BASF (BASFY.PK) as an additional Vascepa active pharmaceutical ingredient supplier. Comment! [Healthcare]
Wednesday, December 19, 2012, 10:26 AM In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of 2030, Amarin (AMRN -0.7%) says it submitted a Supplemental New Drug Application to the FDA seeking approval for Chemport, Inc. as an additional Vascepa active pharmaceutical ingredient supplier. The submission is part of the company's goal to expand and protect its manufacturing supply chain. Comment! [Healthcare]

ajbrzoz
$AMRN key to anticipated yes to NCE is Vascepa being a prodrug,see pg 19, 1st full paragraph: http://1.usa.gov/ZREP5j
8 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
$AMRN loses $60 million on $2 million in sales, denied NCE status, stock almost green, longs loving it. Welcome to bizzaro world. $AMRN
Fri, 2:38 PM
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: Fish oil and the vagina are the two most powerful and mysterious forces in the universe.
Fri, 2:46 PM
• !Report Abuse
hatvani: When did the NCE decision come out?
Fri, 4:51 PM
• !Report Abuse
Add a reply...

140 characters

ajbrzoz
$AMRN 14 patents in FDA Orange Book, more on the way. Combo data to be released by end of June, per CEO.
Thu, 10:26 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
Amarin looking much shakier in trading today than the past few days $AMRN.
Thu, 10:15 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
Amarin pulls back under 50DMA, off 5% today after its recent near 20% move up. $AMRN, $SPY http://seekingalpha.com/a/usbh
Wed, 3:23 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

fire0nice228
$AMRN up big the last 3 trading days, around 10% as of 10:50a Tuesday
Tue, 10:52 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
$AMRN scipt data comes in light this Sunday; cash still burning, scripts barely a 6% gain. http://seekingalpha.com/a/uhat
Mon, 8:08 AM
Reply (3)

• !Report Abuse
View all 3 replies
Quoth the Raven: I own both calls and puts.
Mon, 4:39 PM
• !Report Abuse
Jareleft: Good medicine always sell well, &AMRN will be appreciated as it deserves, time will tell. Luck in your investments
Tue, 2:01 AM
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
Stocks to watch this week ... http://bit.ly/10QDENX ... $TROV, $AMRN, $SNWV.OB, $ANTB.OB, $APHY.OB, $KERX
May 12, 4:06 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

fire0nice228
$AMRN is on a good pace for scripts, tracking well, up 6% today as of 12:39p
May 10, 12:39 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
Still not sold on Amarin. $AMRN http://seekingalpha.com/a/uhat
May 9, 9:08 PM
Reply (1)

• !Report Abuse
View all 1 replies
fire0nice228: Why delete your ST from Friday about $AMRN popping green and ending red everyday? Because it was totally wrong and you got called on it?
May 12, 1:47 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Quoth the Raven
$AMRN loses $60 million on $2 million in sales, denied NCE status, stock almost green, longs loving it. Welcome to bizzaro world. $AMRN
Fri, 2:38 PM
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: Fish oil and the vagina are the two most powerful and mysterious forces in the universe.
Fri, 2:46 PM
• !Report Abuse
hatvani: When did the NCE decision come out?
Fri, 4:51 PM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
$AMRN scipt data comes in light this Sunday; cash still burning, scripts barely a 6% gain. http://seekingalpha.com/a/uhat
Mon, 8:08 AM
Reply (3)

• !Report Abuse
View all 3 replies
Quoth the Raven: I own both calls and puts.
Mon, 4:39 PM
• !Report Abuse
Jareleft: Good medicine always sell well, &AMRN will be appreciated as it deserves, time will tell. Luck in your investments
Tue, 2:01 AM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
Amarin $AMRN burns $58 million in Q1. Holy hell. Potential to be out of cash before 2013 if things don't pick up big-time for Vascepa.
May 9, 4:17 PM
Reply (2)

• !Report Abuse
View all 2 replies
fire0nice228: you should delete this $AMRN comment too. You deleted a bad call on AMRN from Friday, don't forget about this one!
May 12, 1:51 PM
• !Report Abuse
Quoth the Raven: $AMRN scripts only up 5%!
May 12, 9:21 PM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
Still not sold on Amarin. $AMRN http://seekingalpha.com/a/uhat
May 9, 9:08 PM
Reply (1)

• !Report Abuse
View all 1 replies
fire0nice228: Why delete your ST from Friday about $AMRN popping green and ending red everyday? Because it was totally wrong and you got called on it?
May 12, 1:47 PM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
All eyes on Amarin after hours...what will the next chapter in the Amarin story be? $AMRN $SPY
May 9, 2:46 PM
Reply (1)

• !Report Abuse
View all 1 replies
joe kelly: Men will argue the benefits of fish oil.
May 9, 2:56 PM
• !Report Abuse
Add a reply...

140 characters

mitrado
$AMRN & $SPPI trading at the same levels up to the last cent. It's only the 1000th time it happens, in the last year. Coincidence, for sure!
May 2, 10:23 AM
Reply (1)

• !Report Abuse
View all 1 replies
mitrado: $AMRN drops to $6.99... not much longer until $SPPI does exactly the same.
May 2, 1:05 PM
• !Report Abuse
Add a reply...

140 characters

Brian L. Wilson
$AMRN followers - vascepa picked up growth again, and should support pps. More info here http://bit.ly/16brmYv
Apr 29, 7:49 AM
Reply (2)

• !Report Abuse
View all 2 replies
William LeGro: Be still my heart! Almost up to $7! Shhh! Don't tell the shorts!
Apr 29, 1:16 PM
• !Report Abuse
William LeGro: Whoa! Possible stock offering? HZNP already pulled that on its investors. Don't want to see AMRN do it too, I can take only so much trauma.
Apr 29, 1:21 PM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
Amarin downgraded $AMRN http://bit.ly/10Eh0PX
Apr 25, 11:03 PM
Reply (3)

• !Report Abuse
View all 3 replies
Quoth the Raven: Hey, don't get mad at me, I'M not the one that downgraded it! Cheers! ~QTR
Apr 26, 7:55 AM
• !Report Abuse
JMattius: And look at it tank. Think they need more downgrades......
Apr 26, 11:13 AM
• !Report Abuse
Add a reply...

140 characters

mitrado
$AMRN sell-off continues no matter what happens to the company. The stock is trading as if the company doesn't even exist.
Apr 24, 9:43 AM
Reply (8)

• !Report Abuse
View all 8 replies
rapsfan: @hatvani I bought at $7, should have sold at $14; hate that I got greedy
Apr 25, 4:43 PM
• !Report Abuse
hatvani: My initial batch was at 9. Added more at 11.5 after the approval hoping for a rebound.
Apr 26, 3:51 AM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
Reality is starting to sink in for Amarin. Execute Vascepa launch correctly, or the company is heading for dilution. RT $6.39 $AMRN
Apr 25, 3:35 PM
Reply (2)

• !Report Abuse
View all 2 replies
Chris DeMuth Jr.: Snake oil salesmen. Wait, no, that's fish oil salesmen.
Apr 25, 3:46 PM
• !Report Abuse
realornot: I like snake !
Apr 25, 3:57 PM
• !Report Abuse
Add a reply...

140 characters

Derek2012
$AMRN this stock is dead, people losing their money. Stay away people
Apr 10, 9:45 AM
Reply (4)

• !Report Abuse
View all 4 replies
mitrado: I hope you remember that, someday in the future, when this stocks trades above $30.
Apr 12, 1:17 PM
• !Report Abuse
mitrado: Take a look at $VRTX now. I got in @ $30 while profits were rising & stock was falling. Sold at $54. Now it's losing money & it goes to $80.
Apr 19, 6:04 AM
• !Report Abuse
Add a reply...

140 characters

flech3
$AMRN Are we looking at NCE decision tomorrow?
Mar 14, 5:58 PM
Reply (1)

• !Report Abuse
View all 1 replies
LEIGHDIST: flech the NCE is next week only so lets hope for the best,
Apr 4, 2:04 PM
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
$AMRN - nice rebound, but without NCE and lack of solid news, downside still exists...buying opp... http://seekingalpha.com/a/ry1j
Mar 28, 12:30 PM
Reply (1)

• !Report Abuse
View all 1 replies
Rager500: Much Agreed!!
Mar 29, 9:41 PM
• !Report Abuse
Add a reply...

140 characters

Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it.
Mar 29, 5:26 AM
Reply (3)

• !Report Abuse
View all 3 replies
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
Mar 29, 5:18 PM
• !Report Abuse
yourmama6799: Rashar for President!!!
Mar 29, 6:43 PM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
what is going on with $AMRN today, could this stock get any worse??
Feb 21, 2:46 PM
Reply (9)

• !Report Abuse
View all 9 replies
LEIGHDIST: i been long to freaken long at this point i avg around $12.00 so i really long at this point i guess i'll just have to buy more and avg down
Mar 1, 9:36 AM
• !Report Abuse
mitrado: Well, the question is... average down until when? $5 $1? I've re-entered Amarin around $10.5, thinking the panic was too much already. :-/
Mar 27, 8:38 AM
• !Report Abuse
Add a reply...

140 characters

AMRN Amarin Corporation PLC

AMRN

Amarin Corporation PLC